32 min
Scrip M&A Podcast: Pfizer/Seagen and What May Follow Citeline Podcasts
-
- Business
Scrip senior writer Joseph Haas overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and what that may mean for pharma M&A during the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.
Scrip senior writer Joseph Haas overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and what that may mean for pharma M&A during the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.
32 min